Clinical Trials on Relapsed or Refractory Peripheral T-Cell Lymphoma in China

Total 585 results

Waterstone Hanxbio Pty Ltd

Recruiting

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Relapsed/Refractory Lymphoma

China
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
Shandong Provincial Hospital

Unknown

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Relapsed/Refractory Non-Hodgkin's Lymphoma

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Recruiting

A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
Fudan University

Recruiting

ZR-CHOP in DLBCL With Specific Gene Abnormality

Diffuse Large B Cell Lymphoma

China
Beijing Boren Hospital

Terminated

A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors

Advanced Solid Tumor | Relapsed/Refractory Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (ORIENT-1)

Relapsed/Refractory Classical Hodgkin's Lymphoma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

China
Affiliated Hospital to Academy of Military Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking...

Recruiting

Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Age Range ≥16 Years, Gender Unlimited | Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma | Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed | At Least One Positive Lesion According to the 2014... and other conditions

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Relapsed/Refractory Lymphoma

China
Shandong Provincial Hospital

Recruiting

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

China
Beijing Boren Hospital

Recruiting

Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children

Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia

China
Shandong Provincial Hospital

Recruiting

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | B-cell NonHodgkin Lymphoma

China
Chinese PLA General Hospital

Recruiting

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Advanced Solid Tumors | Relapsed/Refractory Non-Hodgkin Lymphoma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Pediatric ALL

China
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (Celestimo)

Relapsed or Refractory Follicular Lymphoma

United States, Korea, Republic of, Taiwan, China, Spain, United Kingdom, Australia, France, Germany, Japan, Turkey, Brazil, Poland, Ukraine, Italy, Russian Federation
Huiqiang Huang
Guangdong 999 Brain Hospital

Not yet recruiting

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

Non Hodgkin Lymphoma | PCNSL | Refractory and Relapsed Primary CNS Lymphoma

China
Fudan University

Recruiting

Gene Abnormalities and Prognosis in Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma, Gene Mutation

China
Tarapeutics Science Inc.

Recruiting

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Advanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

China
BeiGene

Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

Marginal Zone Lymphoma | Relapsed/Refractory Follicular Lymphoma

United States, Italy, Spain, China, United Kingdom, Australia, Israel, Korea, Republic of, Belgium, France, Brazil, Ireland, Czechia, Romania, Portugal, Georgia, Argentina, Poland, Puerto Rico, Austria, Switzerland
He Huang

Recruiting

Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia

AIDS Related Lymphoma and Lympholeukemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Lymphoblastic Leukemia, Acute, Childhood | Refractory Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Relapsed Leukemia

China
Second Affiliated Hospital, School of Medicine,...

Active, not recruiting

A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma | Refractory Central Nervous System Lymphoma | Relapsed Primary Central Nervous System Lymphoma

China
First Affiliated Hospital of Wenzhou Medical University
Second Affiliated Hospital of Nanchang University; Hrain Biotechnology Co.,...

Unknown

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia

China
Henan Cancer Hospital

Recruiting

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma | CD79A Gene Mutation | CD79B Gene Mutation

China
Aibin Liang，MD，Ph.D.
CARsgen Therapeutics Co., Ltd.

Recruiting

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Relapsed and/or Refractory Multiple Myeloma | Plasma Cell Leukemia in Relapse

China
BeiGene

Recruiting

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma | Leukemia | Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Relapsed Chronic Lymphocytic Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Refractory Hodgkin Lymphoma | Relapse | Hodgkin Lymphoma, Adult

China
Fudan University

Recruiting

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Diffuse Large B-cell Lymphoma

China
Guangzhou FineImmune Biotechnology Co., LTD.

Recruiting

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors (TAL-T)

Advanced Solid Tumor | Immunotherapy | Tumor Associated Lymph Node T Cell

China
The First Affiliated Hospital of Soochow University
Fundamenta Therapeutics, Ltd.

Recruiting

ThisCART19A for B-NHL Relapsed After Auto-CAR T

B Cell Lymphoma | CAR | Relapsed Non-Hodgkin Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital; Shandong Cancer Hospital...

Recruiting

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

B7-H3-positive Relapsed/ Refractory Neuroblastoma

China
Chinese PLA General Hospital

Recruiting

Decitabine and Anti-PD-1 in R/R DLBCL

Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma | Extranodal Extension | Relapse/Recurrence

China
Epizyme, Inc.

Recruiting

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular Lymphoma

United States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
Yang Yang

Unknown

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

Stage IV Adult Hodgkin Lymphoma | Stage IV Nasopharyngeal Carcinoma | Stage IV Diffuse Large B-Cell Lymphoma | Stage IV Gastric Carcinoma | T-Cell Lymphoma Stage IV

China
Fujian Medical University

Unknown

CART-19 Cells For R/R B-ALL (CCFRRBA)

Relapsed/Refractory B-cell ALL

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Terminated

CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)

Refractory and Relapsed B Cell Acute Leukemia

China
Xinhua Hospital, Shanghai Jiao Tong University...

Unknown

G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor

Lymphoma | Acute Myeloid Leukemia | Neuroblastoma | Retinoblastoma | Hepatoblastoma | Acute Lymphoid Leukemia

China
Samsung Medical Center

Completed

Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab

Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma | Patients Treated With Rituximab-CHOP or Rituximab-CVP

Korea, Republic of, Malaysia, Singapore, China
Sinocelltech Ltd.

Recruiting

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Relapsed or Refractory Hematologic Malignancies

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

Relapsed / Refractory Follicular Lymphoma

China
Shandong University
Juventas Cell Therapy Ltd.

Unknown

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Relapsed or Refractory Hematological Malignancies

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Peking University People's Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Recruiting

PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Plasmacytoid; Lymphoma

China
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Relapsed Non Hodgkin Lymphoma

China
Affiliated Hospital to Academy of Military Medical...
Beijing JD Biotech Co. LTD.

Recruiting

CAR-NK Targeted CD19 for r/r B-cell Malignancies

Adult Relapsed/Refractory B-cell Hematologic Malignancies

China
Kai Lin Xu; Jun Nian Zheng
iCarTAB BioMed Inc.

Unknown

CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

Recurrent or Refractory B Cell Malignancy

China
The Affiliated People's Hospital of Ningbo University
UTC Therapeutics Inc.

Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Lymphoma | Leukemia | Myeloma | Relapsed/Refractory Hematological Malignancies

China

Clinical Trials on Relapsed or Refractory Peripheral T-Cell Lymphoma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations